Hinova doses first patient in Phase I castration-resistant prostate cancer trial
HP518 is highly selective for AR, a therapeutic target which has been validated for prostate cancer treatment.
Australia
Latest in
Australia
Trial Activity Snapshot: Did Australia’s “zero-Covid” plan protect clinical trial activity?
In an exclusive, Clinical Trials Arena dives into Australia’s trial activity data to find out how the pandemic impacted the…
By
Sciwind commences dosing in Phase IIb obesity drug trial
The trial will be carried out in Australia and New Zealand, and will enrol nearly 200 patients with obesity.
PharmAbcine doses first subject in Phase II mTNBC combo therapy trial
The trial will enrol 36 mTNBC patients who are immuno-oncology therapy naive, irrespective of the PD-L1 status.
Antengene doses first participant in tumour treatment trial in Australia
The trial will analyse safety and tolerability of ATG-101 and detect its maximum tolerated dose as primary goal.
Zydus to commence Phase IIa CAPS trial of drug in Australia
The trial will assess ZYIL1’s safety, tolerability, PK and PD in people with CAPS.
Starpharma reports positive Phase II interim data for prostate cancer
DEP cabazitaxel treatment provided 64% of subjects with assessable tumour lesions a decline in tumour size for up to 36…
BeiGene commences Phase I trial of TYK2 inhibitor BGB-23339
The trial will analyse the safety, tolerability, pharmacokinetics and initial activity of BGB-23339 in healthy people.